CURRENT SITUATION OF ADJUVANT CHEMOTHERAPY FOR STAGE II/III GASTRIC CANCER IN OUR HOSPITAL

    loading  Checking for direct PDF access through Ovid

Abstract

Background

We retrospectively analyzed the efficacy of adjuvant chemotherapy in patients with stage II/III gastric cancer. The standard of care for stage II/III gastric cancer in Japan is curative gastrectomy and adjuvant chemotherapy with S-1 for 1 year. We retrospectively analyzed the feasibility and the outcome of adjuvant chemotherapy in our hospital.

Method

We analyzed about the feasibility and outcome of adjuvant chemotherapy with stage II/III gastric cancer patients who had undergone curative gastrectomy in our hospital between 2007 and 2010.

Result

A total of 90 patients were evaluated. Patients' characteristics are shown each of the following: median age, 68 years (range: 43–82); sex (male/female), 61/29; stage (II/III), 60/30; pathology (differentiated/undifferentiated), 48/42. The completion rate with adjuvant chemotherapy was 67% (60/90). Thirty patients discontinued adjuvant chemotherapy due to toxicity (n = 11.37%), recurrence (n = 12.40%) and other reasons (n = 7.30%). Twenty-two patients experienced recurrence. Of the 22 patients, 16 patients experienced early recurrence (recurrence within 6 months after adjuvant treatment). The other six patients experienced non-early recurrence. The median period of observation from recurrence is 2.8 months (range: 0–22.5). The median survival time of early recurrence patients is 6.8 months (range: 0.4–10.0) and non-early recurrence is 3.3 months (range: 1.4–16.7; log-lank P = 0.9974).

Discussion

The completion rate with adjuvant chemotherapy with S-1 in our hospital is 67% that is equivalent to the report of ACTS-GC. It is unclear that the period of recurrence from last administration of S-1 makes effect to overall survival in this retrospective study.

Related Topics

    loading  Loading Related Articles